Product Description
Mechanisms of Action: IDO1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05469490 |
HCC 21-257 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified |
2024-08-01 |
50% |
2022-10-01 |
Primary Endpoints |
NCT02471846 |
GO29779 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2019-10-02 |
12% |
2019-10-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
NCT02048709 |
GO29753 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-02-01 |
2019-03-20 |
Treatments |